AOD-9604: The Fat Loss Peptide You’ll Soon Be Able to Get Again

AOD-9604 is a modified fragment of human growth hormone investigated for its potential effects on fat metabolism. Although laboratory studies suggest that it may influence lipolysis and fat storage, human clinical trials have not established meaningful, sustained weight loss. AOD-9604 is not FDA-approved as a weight-loss medication. Its potential return to legal compounding must be assessed against current FDA requirements; regulatory discussions, petitions, or proposed changes do not constitute authorization. Claims that it will soon become legally available through compounding should therefore be treated cautiously.

Introduction

AOD-9604 has attracted considerable attention in the peptide and weight-management markets because of its proposed ability to influence fat metabolism without reproducing all the effects of full-length human growth hormone. Often described as a fat-loss peptide, it was originally investigated as a potential treatment for obesity, with research focusing on how a small fragment of the growth hormone molecule might affect the breakdown and storage of fat.

Interest in AOD-9604 has expanded beyond its original research setting. Online discussions frequently associate it with fat loss, body recomposition, and experimental peptide therapies. Some commercial claims also suggest that it may become available again through legal compounding in the United States.

However, these claims involve three separate questions: whether AOD-9604 produces clinically meaningful weight loss, whether its safety has been adequately established, and whether current US regulations permit its compounding. Evidence supporting one of these propositions does not automatically establish the others.

Understanding AOD-9604 requires looking beyond its proposed biological mechanism. Its human clinical trials, formulation-specific evidence, potential adverse effects, and regulatory history all affect how its claims should be interpreted.

This guide examines the available scientific evidence, compares AOD-9604 with established weight-management medications, and explains why claims about its renewed availability require careful regulatory verification.

What Is AOD-9604?

AOD-9604 is a synthetic, 16-amino-acid peptide derived from the C-terminal region of human growth hormone (hGH). It was developed as an experimental anti-obesity compound to investigate whether the hormone's proposed fat-metabolism effects could be separated from its growth-promoting and other metabolic effects.

The name AOD stands for anti-obesity drug. AOD-9604 is also described as a modified growth hormone fragment, although it is not equivalent to full-length growth hormone.

Illustrative peptide molecular structure; not a laboratory image of AOD-9604.

Molecular identity and origin

AOD-9604 was developed by Australian pharmaceutical researchers investigating the possibility of separating fat metabolism from the other biological activities of human growth hormone.

It corresponds to the C-terminal region of growth hormone, commonly described as hGH(177–191), with an additional tyrosine residue at the N-terminus. This modification produces a 16-amino-acid peptide.

The rationale was that a smaller fragment might retain certain lipolytic properties without activating the same pathways responsible for growth hormone's effects on tissue growth and insulin sensitivity.

However, a compound's molecular origin does not establish that it reproduces the desired effects of the original hormone in humans.

How AOD-9604 differs from human growth hormone

Full-length human growth hormone is a protein hormone that binds to the growth hormone receptor and influences several biological processes, including growth, metabolism and the production of insulin-like growth factor 1 (IGF-1).

AOD-9604 was designed to investigate a different approach. Researchers hypothesized that its fragment could influence fat metabolism without producing the broader effects associated with full-length growth hormone.

The distinction matters because AOD-9604 is not simply a shorter version of growth hormone with identical pharmacological properties.

Why was AOD-9604 investigated for obesity?

Researchers initially investigated AOD-9604 because laboratory experiments suggested that the peptide could influence the breakdown of stored fat. Animal studies also produced findings that justified further investigation in humans.

Its development subsequently progressed to clinical trials involving adults with obesity. Those studies were intended to determine whether the proposed biological effects translated into meaningful weight reduction.

The clinical development program ultimately failed to establish sufficient weight-loss efficacy, and development for obesity was discontinued.

AOD-9604 is therefore best understood as an investigational compound with a history of obesity research, not as an established obesity medication.

How Does AOD-9604 Work?

AOD-9604 was designed around the hypothesis that a fragment of human growth hormone could influence fat metabolism without activating the hormone's full range of biological pathways. Preclinical experiments suggest possible effects on lipolysis and lipogenesis, but its precise mechanism in humans remains insufficiently established.

Proposed effects on lipolysis

Lipolysis is the process by which stored triglycerides are broken down into fatty acids and glycerol. These substances can subsequently be used or processed by the body.

In laboratory and animal experiments, AOD-9604 demonstrated lipolytic activity. Researchers investigated whether it could increase the mobilization of stored fat in adipose tissue, which is the tissue responsible for storing most of the body's fat.

Some preclinical experiments also investigated changes in beta-3 adrenergic receptor activity. These findings provided a possible explanation for the observed metabolic effects in animal models.

However, the proposed signaling pathways have not been sufficiently validated in humans to establish a reliable clinical mechanism.

Proposed effects on lipogenesis

Lipogenesis is the process through which the body synthesizes and stores fat.

Some laboratory studies suggest that AOD-9604 may inhibit lipogenesis under experimental conditions. This finding contributed to the hypothesis that the peptide could affect both fat breakdown and fat storage.

However, changes in lipogenesis in cultured cells do not establish that a person taking a particular formulation will experience a meaningful reduction in body fat.

Fat mobilization is not the same as weight loss

The distinction between fat mobilization and sustained weight loss is fundamental to interpreting AOD-9604 research.

A compound may influence the release of fatty acids from fat cells without producing a lasting reduction in total body fat. The body can also compensate for changes in energy expenditure, food intake and substrate utilization.

Meaningful weight reduction generally requires a sustained change in energy balance. It also involves biological adaptations that can make maintaining weight loss difficult.

Consequently, even if AOD-9604 influences lipolysis under certain conditions, this alone would not establish it as an effective obesity treatment.

Does it avoid the effects of growth hormone?

AOD-9604 was specifically developed to investigate whether some fat-related effects could occur without the broader effects of full-length growth hormone.

Preclinical findings suggest that it does not reproduce conventional growth hormone receptor activation. Early human studies also investigated metabolic safety, including potential effects on glucose regulation.

Nevertheless, a proposed separation of biological effects is not proof of complete safety. The available evidence cannot establish that every formulation or potential use of AOD-9604 is free from clinically important risks.

What Are the Potential Benefits of AOD-9604?

The potential benefits of AOD-9604 are primarily research hypotheses rather than established therapeutic outcomes. Its most frequently discussed applications involve fat metabolism and obesity, but clinical evidence has not established that it reliably produces meaningful weight loss or improves body composition.

Fat metabolism

The most prominent proposed benefit of AOD-9604 is its potential influence on fat metabolism. Preclinical experiments provide a biological rationale for further investigation, but the results do not establish an effective treatment for human obesity.

Weight management

AOD-9604 was investigated specifically for obesity. Its clinical development included human trials designed to assess weight reduction, but the later efficacy findings did not justify continued development as an obesity medication.

Body composition and lean mass

Fat mass and lean mass are separate measures. A reduction in total body weight does not necessarily mean that fat mass has decreased proportionately.

Although some animal research examined changes in adipose tissue and lean body mass, those observations cannot establish that AOD-9604 preserves muscle in humans. Claims of improved body composition therefore remain inadequately supported.

Appetite suppression

Appetite suppression is another frequently advertised property, but it should not be confused with the peptide's proposed effects on fat metabolism. There is insufficient controlled human evidence to classify AOD-9604 as a clinically established appetite suppressant.

Overall, its proposed benefits remain constrained by the gap between preclinical findings and human clinical outcomes.

Does AOD-9604 Actually Work for Weight Loss?

AOD-9604 has been tested in human obesity research, so its weight-loss claims are not based exclusively on laboratory experiments. However, its pivotal clinical development did not establish a statistically significant, clinically useful benefit over placebo, leaving its effectiveness for weight loss unproven.

Human clinical research

AOD-9604 underwent a series of clinical investigations during its development. These included early safety and dose-ranging studies and larger trials involving adults with obesity.

The clinical program investigated oral formulations and assessed whether the proposed metabolic effects translated into reductions in body weight.

The results were mixed during the earlier development stages. Although an initial 12-week study generated interest in a possible weight-loss signal, subsequent research did not establish a sufficiently reliable therapeutic effect.

The pivotal 24-week study

The most consequential finding came from the larger, 24-week Phase IIb obesity trial. The study investigated AOD-9604 in adults with obesity and compared its effects with placebo.

The trial did not establish statistically significant weight-loss efficacy at the investigated doses. The absence of a convincing treatment effect contributed to the discontinuation of the obesity development program in 2007.

The findings are particularly relevant because a large, controlled trial provides more useful evidence of efficacy than isolated testimonials or animal experiments.

Why the results matter

A statistically significant result indicates that an observed difference is unlikely to be explained by chance alone under the assumptions of the statistical analysis. Clinical significance, however, concerns whether that difference is large enough to matter to patients.

Even a statistically significant reduction in weight would not automatically establish that a compound is clinically useful. Researchers must also consider the magnitude of the effect, its duration, the study population and potential adverse effects.

In AOD-9604's case, the pivotal efficacy findings did not establish a sufficiently convincing treatment effect to support continued obesity development.

Why preclinical findings cannot override human trials

Animal experiments are useful for investigating biological mechanisms and generating hypotheses. However, metabolism, drug absorption, receptor activity and energy regulation can differ substantially between species.

A compound that reduces weight gain in obese mice may not produce a comparable effect in humans. Human trials are therefore essential for establishing whether the proposed benefit translates into clinical practice.

For AOD-9604, the available human efficacy findings are a significant limitation that cannot be resolved simply by citing positive animal research.

AOD-9604 Results: What Does the Evidence Show?

AOD-9604 results must be interpreted in the context of controlled clinical research rather than promotional claims. Human studies investigated its potential for weight reduction, but the overall clinical program failed to establish sustained, clinically meaningful efficacy.

The main findings to consider are:

• Weight-related outcomes: Clinical development included controlled obesity trials, with the pivotal 24-week study failing to establish a significant treatment benefit.
• Duration: Evidence from relatively short studies cannot establish whether any initial changes would persist over several years.
• Body composition: Changes in body weight and changes in fat mass are not interchangeable. Evidence for a clinically meaningful improvement in body composition remains inadequate.
• Individual experiences: Testimonials and reviews may describe perceived changes, but they cannot isolate the effect of AOD-9604 from diet, physical activity or other interventions.

An AOD-9604 review should also distinguish the original clinical research from newer commercial claims. Advertised results, including claims of predictable fat reduction, should not be treated as independently verified outcomes.

The available evidence does not establish a reliable timeframe for visible fat loss or demonstrate that a particular result is typical.

AOD-9604 Before and After: Are the Results Real?

AOD-9604 before-and-after photographs are sometimes used in peptide marketing to suggest that the compound produces rapid fat loss. However, photographs cannot establish that AOD-9604 caused a change in someone's appearance or that similar results can be expected by other people.

Several factors can influence before-and-after comparisons:

• Lighting: Changes in illumination can alter the apparent definition of muscles and body contours.
• Camera angles: Different perspectives can make the waist, abdomen and other body areas appear substantially different.
• Hydration: Changes in fluid balance can affect body weight and appearance.
• Diet and exercise: Dietary changes and physical activity can independently affect body composition.
• Image selection: Selecting photographs from different conditions or time periods can exaggerate apparent changes.

Searches for AOD-9604 before-and-after pictures, including one-month results, often reflect interest in visible outcomes. However, a photograph alone does not establish the amount of fat lost, the duration of the change or its cause.

Reliable evaluation requires objective measurements, appropriate controls and a clearly defined study period. Randomized clinical trials are designed to reduce the influence of factors that make testimonials difficult to interpret.

There is no scientifically established, typical one-month before-and-after result for AOD-9604. Claims of dramatic changes over a specific period should be assessed against actual human clinical evidence.

AOD-9604 vs. Semaglutide: What Are the Differences?

AOD-9604 and semaglutide have fundamentally different molecular structures and mechanisms. Semaglutide has substantial randomized clinical trial evidence and FDA-approved weight-management indications, whereas AOD-9604 has not demonstrated comparable weight-loss efficacy in its clinical development program.

AOD-9604

An experimental growth hormone fragment investigated for its potential effects on fat metabolism.

Semaglutide

A GLP-1 receptor agonist with established effects on appetite regulation and glucose metabolism.

Comparison of AOD-9604 and semaglutide

Different biological mechanisms

AOD-9604 was designed around the hypothesis that part of the growth hormone molecule might influence fat metabolism. Its precise clinical mechanism remains uncertain.

Semaglutide works through GLP-1 receptors. These receptors participate in the regulation of blood glucose, appetite and food intake. The drug's weight-management effects have been investigated in large randomized trials.

The two compounds should not be treated as interchangeable simply because both appear in weight-loss discussions.

Differences in clinical evidence

Semaglutide has undergone extensive clinical investigation for chronic weight management. Its evidence base includes large trials that evaluated body weight and other clinically relevant outcomes over extended periods.

AOD-9604 has a much more limited efficacy record. Its pivotal obesity trial failed to establish the treatment effect required for continued development.

These differences are important when interpreting claims about their potential effects. Semaglutide's clinical results cannot be used as evidence that AOD-9604 will produce comparable outcomes.

Differences in regulatory status

Semaglutide is the active ingredient in FDA-approved medications, including Wegovy for specified weight-management indications. AOD-9604 has no FDA-approved therapeutic indication.

Approval of a semaglutide medication does not mean that every compounded semaglutide product is automatically lawful. Similarly, the absence of FDA approval for AOD-9604 is a separate issue from the specific federal requirements governing compounded preparations.

AOD-9604 vs. Tirzepatide: Key Differences

AOD-9604 and tirzepatide differ in molecular structure, biological activity, clinical evidence and regulatory status. Tirzepatide has been studied in large weight-management trials and is an active ingredient in FDA-approved medications, while AOD-9604 remains an experimental peptide without established weight-loss efficacy.

Comparison of AOD-9604 and tirzepatide

How tirzepatide works

Tirzepatide acts on two incretin hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

These pathways influence glucose regulation, appetite and energy intake. Tirzepatide has been investigated in large clinical trials involving adults with obesity or overweight and relevant weight-related conditions.

Its efficacy and safety have been evaluated in a substantially larger clinical program than that of AOD-9604.

Why their research results differ

AOD-9604 was investigated primarily as a potential fat-metabolism intervention. Tirzepatide's clinical weight-management effects involve established incretin receptor pathways and have been evaluated using randomized trials with clinically relevant endpoints.

AOD-9604's unsuccessful pivotal trial means its proposed mechanism has not translated into established obesity-treatment efficacy.

Tirzepatide's clinical evidence cannot be transferred to AOD-9604 simply because both compounds are discussed in the context of weight loss.

Regulatory distinctions

Zepbound is an FDA-approved tirzepatide product for specified indications, including chronic weight management in eligible adults. Mounjaro is another FDA-approved tirzepatide product, with a separate diabetes indication.

AOD-9604 has no comparable FDA-approved drug product. Its potential compounding status must be assessed independently of the regulatory status of tirzepatide.

AOD-9604 With Tirzepatide: Is There Evidence for Combining Them?

There is insufficient controlled human evidence to establish that combining AOD-9604 with tirzepatide improves weight loss, body composition or long-term outcomes. The fact that the compounds have different proposed mechanisms does not demonstrate that using them together is effective or safe.

The combination is sometimes discussed online because AOD-9604 is marketed for fat metabolism while tirzepatide has established effects on appetite regulation and weight management.

However, these proposed complementary effects remain a hypothesis rather than a validated clinical strategy.

There are several important evidence gaps:

• No established body of controlled human trials demonstrates that the combination provides additional weight loss.
• The safety of combining the compounds has not been adequately characterized.
• The effects of different formulations and exposure levels cannot be assumed to be predictable.
• Evidence supporting tirzepatide alone does not establish the effectiveness or safety of an additional investigational peptide.

Combining compounds can also complicate the assessment of adverse events. When multiple substances are used simultaneously, identifying the cause of an unexpected reaction becomes more difficult.

Without suitable clinical studies, it is not possible to establish whether adding AOD-9604 to tirzepatide provides additional benefits or introduces avoidable risks.

AOD-9604 and Appetite Suppression

AOD-9604 is not an established appetite suppressant. Its original research focused on fat metabolism rather than the appetite-regulating pathways targeted by medications such as semaglutide and tirzepatide.

Appetite is regulated by a complex interaction between the brain, gastrointestinal tract, hormones and energy availability. GLP-1 and GIP pathways are relevant to this regulation, which is one reason incretin-based medications have been investigated for weight management.

AOD-9604's proposed effects are different. Its development focused on whether a growth hormone fragment could influence fat breakdown and storage. Preclinical evidence of lipolysis does not establish that the compound reduces hunger or food intake in humans.

Although appetite changes may be mentioned in individual testimonials, these accounts cannot establish a reproducible pharmacological effect.

The available evidence does not justify describing AOD-9604 as an established appetite suppressant or assuming that it works through the same pathways as approved incretin-based weight-management medications.

AOD-9604 Side Effects and Safety

AOD-9604 has been evaluated in human safety studies, but the available research does not establish comprehensive long-term safety. Findings from controlled trials can inform discussions of tolerability, yet they cannot guarantee the safety of every formulation, population or potential use.

What human trials report

AOD-9604 underwent multiple clinical investigations during its development. Some publications have summarized safety and tolerability findings from six randomized, double-blind, placebo-controlled human trials.

These investigations provide information about short-term tolerability under specific research conditions. However, safety findings must be interpreted in light of the participants, formulations, exposure periods and adverse-event monitoring used in the individual trials.

The reported tolerability of an experimental formulation does not demonstrate that commercially marketed versions have the same safety profile.

Potential adverse effects and evidence limitations

Clinical research has not established a comprehensive list of adverse effects that applies to all AOD-9604 products and uses.

The principal limitations include:

• Limited long-term evidence: Short clinical trials cannot establish the consequences of prolonged exposure.
• Formulation differences: The safety of one studied formulation cannot automatically be transferred to another.
• Limited population data: Findings from particular study populations do not necessarily apply to everyone.
• Uncertain product quality: Unapproved products may differ in identity, purity, concentration and sterility.
• Incomplete evidence: The absence of a reported adverse event in a relatively small trial does not establish that the event cannot occur.

It is also important to distinguish documented adverse events from theoretical risks. Potential concerns associated with poor-quality products should not be misrepresented as confirmed pharmacological side effects of the peptide itself.

Product quality and unapproved formulations

Product quality is an independent safety consideration. An experimental peptide's identity, purity, stability and sterility can influence the risks associated with a particular product.

Commercial claims about laboratory testing or purity do not establish FDA approval or demonstrate that a product meets all applicable pharmaceutical quality requirements.

These concerns are particularly relevant when the marketed formulation differs from the formulation investigated in published research.

AOD-9604 side effects in women

Available clinical research does not establish a distinct, comprehensive female-specific adverse-effect profile for AOD-9604. Limited evidence should not be interpreted as proof that women experience no additional risks.

A reliable assessment would require sufficiently large studies with appropriate representation of women, clearly reported adverse events and adequate follow-up. The current evidence does not justify claims of established safety for women across different formulations or circumstances.

Is AOD-9604 Safe?

AOD-9604 has undergone human safety investigations, but its long-term safety and the safety of many commercially marketed formulations remain uncertain. Short-term tolerability findings cannot establish that an unapproved peptide is universally safe or appropriate for weight management.

The distinction between tolerability and safety is important. A study may report no major safety signal among its participants while still being too small or too short to identify uncommon or delayed adverse effects.

Safety also depends on the specific formulation and the quality of the product. Research involving a controlled investigational formulation does not necessarily describe the risks associated with products sold outside regulated pharmaceutical channels.

Unlike FDA-approved medications with established prescribing information, AOD-9604 has no FDA-approved drug label defining its indications, contraindications and validated risk profile.

Its available evidence therefore supports a limited conclusion: some human studies have examined its tolerability, but comprehensive long-term safety has not been established.

AOD-9604 Oral, Nasal Spray, and Troche Formulations

AOD-9604 has been investigated in oral clinical formulations, but evidence for one formulation cannot establish the effectiveness of every commercially advertised product. Nasal sprays and troches require separate evidence because their absorption, stability and exposure may differ.

Oral AOD-9604

Oral formulations were part of AOD-9604's original clinical development program. Investigators explored whether an orally administered formulation could be useful in obesity research.

However, studying an oral formulation is not equivalent to demonstrating that every oral AOD-9604 product is effective. The pivotal obesity research did not establish sufficient clinical efficacy to support AOD-9604 as an approved oral weight-loss treatment.

Peptide absorption can be influenced by degradation in the gastrointestinal tract, molecular characteristics and formulation. Consequently, results from one experimental formulation cannot automatically be applied to an unrelated commercial product.

AOD-9604 nasal spray

Nasal spray products are sometimes discussed in online peptide markets. However, adequate controlled human evidence establishing the effectiveness of commercially marketed AOD-9604 nasal sprays for weight loss is lacking.

The nasal route can affect drug absorption, but this general pharmacological principle does not demonstrate that a specific AOD-9604 nasal formulation achieves reliable exposure or produces meaningful clinical outcomes.

AOD-9604 troches

Troches are preparations designed to dissolve in the mouth. Their absorption can differ from that of swallowed oral products or other delivery systems.

Claims that AOD-9604 troches provide reliable fat loss should be treated cautiously unless supported by appropriate formulation-specific human trials.

Why formulation matters

Commercial availability of a particular formulation does not establish its clinical effectiveness, quality or legal status.

AOD-9604 Dosage and How to Use It

There is no FDA-approved AOD-9604 dosage or validated universal self-administration protocol for weight loss. Experimental doses used in clinical research are specific to the study design and should not be treated as prescribing instructions.

Different clinical studies may use different formulations, research objectives and exposure periods. The findings from one study do not establish an appropriate dose for another formulation or population.

Oral and other formulations should not be assumed to produce equivalent exposure. Differences in absorption and bioavailability can make comparisons between experimental protocols unreliable.

Online dosage charts, peptide therapy discussions and anecdotal protocols do not replace evidence from properly designed clinical trials. They also cannot establish the safety or effectiveness of an unapproved use.

A published research protocol documents what investigators studied under particular conditions. It is not an approved instruction for self-administration.

The distinction is particularly important for AOD-9604 because its clinical development did not establish a successful weight-loss treatment with an approved dosing regimen.

AOD-9604 for Bodybuilding and Body Composition

AOD-9604 is discussed in bodybuilding communities because of its proposed effects on fat metabolism. However, evidence of lipolytic activity does not establish that the peptide builds muscle, preserves lean mass or improves athletic performance.

Fat loss and muscle growth are different physiological outcomes. A substance that influences the breakdown of stored fat does not necessarily stimulate muscle protein synthesis or increase strength.

Some animal experiments investigated changes in fat tissue and lean body mass. These findings provide a basis for scientific questions but do not establish clinically meaningful body-composition benefits in human athletes.

There is also insufficient clinical evidence to conclude that AOD-9604 improves exercise performance, recovery or muscle preservation.

Before-and-after photographs and bodybuilding testimonials are particularly difficult to interpret because training, dietary changes and other substances can independently influence appearance.

AOD-9604 should therefore not be characterized as a proven bodybuilding peptide or a clinically established body-recomposition treatment.

AOD-9604 vs. MOTS-c: What Is the Difference?

AOD-9604 and MOTS-c are distinct experimental peptides with different biological origins and research rationales. AOD-9604 is a modified growth hormone fragment investigated for fat metabolism, whereas MOTS-c is a mitochondrial-derived peptide investigated for its possible roles in cellular metabolism.

AOD-9604's original research focused on lipolysis, lipogenesis and potential obesity treatment. MOTS-c research has examined mitochondrial signaling and metabolic regulation, particularly in laboratory and animal models.

Both compounds have attracted attention in discussions about metabolic health and body composition. However, proposed biological effects do not establish clinical efficacy.

The human evidence for both compounds has important limitations, and neither should be described as an established weight-loss treatment based solely on mechanistic research or testimonials.

Comparing AOD-9604 and MOTS-c therefore requires separating their molecular identities, proposed mechanisms and experimental findings from demonstrated clinical outcomes.

Is AOD-9604 Returning to Legal Compounding?

As of October 1, 2026, the available FDA records do not establish that AOD-9604 is returning to legal compounding. Its previous 503A nomination was withdrawn, it is not established as an FDA-approved drug, and no general authorization for compounded AOD-9604 follows from the withdrawal of its nomination.

Regulatory distinction

A withdrawn nomination is not FDA approval, inclusion on a bulk drug substance list or permission to compound. Claims that AOD-9604 is about to return should be supported by a specific, finalized regulatory action.

What is the current FDA position?

AOD-9604 has been considered in the context of FDA's bulk drug substance nomination process for compounding. However, the regulatory record must be distinguished from claims made by peptide vendors or other commercial sources.

The FDA's records identify AOD-9604 among bulk substances whose nominations were withdrawn. A withdrawn nomination does not establish that the FDA has accepted the substance for routine compounding. Nor does it mean that a previously restricted substance has automatically become eligible.

The distinction is particularly relevant because the FDA has separate regulatory frameworks for traditional compounding under section 503A and outsourcing facilities under section 503B.

What does section 503A allow?

Section 503A establishes conditions under which state-licensed pharmacists and physicians may compound medications for individual patients.

Among other requirements, a bulk drug substance generally must satisfy an applicable United States Pharmacopeia or National Formulary monograph, be a component of an FDA-approved drug product where the relevant statutory conditions apply, or appear on the FDA's 503A bulks list when the applicable conditions are met.

The framework also includes requirements relating to prescriptions, the relationship between compounded products and commercially available drugs, and other statutory conditions.

FDA's interim policies distinguish among nominated substances according to the information available and the safety concerns identified. Category 1 substances may fall within a limited enforcement-discretion policy, whereas category 2 substances have identified safety concerns and are not covered by the same policy. Category 3 substances have insufficient nomination information for that policy.

Importantly, the nomination process is not a substitute for meeting all the other applicable compounding requirements.

What does section 503B allow?

Section 503B governs outsourcing facilities, which are subject to additional federal requirements, including current good manufacturing practice requirements.

The 503B bulk drug substance framework is separate from the 503A framework. A substance's status under one section does not automatically establish eligibility under the other.

Outsourcing facilities must meet the applicable statutory requirements for compounding from bulk substances. A substance being discussed by regulators or appearing in a nomination process is not sufficient by itself to establish that those requirements have been met.

Does a regulatory proposal mean AOD-9604 will return?

No. A nomination, petition, public consultation or advisory discussion is not equivalent to a finalized FDA decision.

Similarly, enforcement discretion means that the FDA may choose not to pursue particular enforcement actions under specified circumstances. It does not confer drug approval, create a general right to compound a substance or establish its effectiveness.

The FDA's compounding policies also continue to evolve. Any claim of renewed eligibility must be checked against the actual final regulatory documents and the requirements applicable to the particular pharmacy or outsourcing facility.

What about commercial availability?

AOD-9604 may be advertised by online sellers or other commercial businesses. However, the existence of a listing, a supplier announcement or an offer to sell the compound does not demonstrate that the product is FDA-approved or lawfully compounded.

State pharmacy laws may impose additional requirements beyond federal rules. Therefore, the legal position can also depend on the state and the specific circumstances.

What the evidence supports: The claim that AOD-9604 will soon return to legal compounding should not be treated as an established fact. Its availability depends on applicable federal and state requirements, not merely on commercial announcements or the withdrawal of a nomination.

AOD-9604 FDA Approval Status

AOD-9604 is not FDA-approved for weight loss or any other therapeutic indication. It has been investigated in clinical trials, but completing clinical research does not constitute FDA approval. Its compounding status is a separate regulatory question.

Has the FDA approved AOD-9604?

No. AOD-9604 has no FDA-approved drug label, approved weight-management indication or established prescribing instructions.

Its historical development as an obesity drug does not change this status. Clinical investigation allows researchers to study a compound under appropriate regulatory conditions; it does not authorize general marketing as an approved medication.

What is the difference between an investigational drug and an approved medication?

An investigational drug is being studied or developed to determine its safety and effectiveness for a particular use. FDA approval generally requires an adequate application and supporting evidence demonstrating that the product meets the applicable statutory and regulatory standards.

AOD-9604's clinical development did not result in FDA approval for obesity treatment.

Does compounding eligibility mean FDA approval?

No. Compounding eligibility and FDA drug approval are separate regulatory matters.

A substance might qualify for certain forms of compounding under applicable statutory requirements without being an FDA-approved drug product. Conversely, a substance's history of clinical investigation or commercial sale does not establish that it qualifies for compounding.

For AOD-9604, neither its historical clinical trials nor the withdrawal of its compounding nomination establishes FDA approval.

Why commercial availability can be misleading

An online product listing does not demonstrate FDA approval, lawful compounding or established clinical efficacy. The regulatory status of the substance, the nature of the product and the applicable federal and state requirements must be considered separately.

The absence of an FDA-approved AOD-9604 medication remains an essential distinction when evaluating claims about its availability.

What Does the Evidence Actually Support?

The available evidence establishes AOD-9604's identity as a synthetic growth hormone fragment and documents its investigation in obesity research. It also identifies substantial limitations: preclinical findings have not translated into established clinical weight-loss efficacy, and important questions about long-term safety and formulation-specific outcomes remain unresolved.

Evidence summary

What is scientifically established?

AOD-9604 is a synthetic peptide based on a region of human growth hormone. Its molecular identity and historical development as a potential obesity treatment are documented.

Laboratory and animal studies provide a rationale for investigating its effects on fat metabolism. However, these findings do not demonstrate that it causes clinically meaningful fat loss in humans.

What have human trials demonstrated?

Human trials investigated AOD-9604 for obesity and examined its tolerability. The pivotal efficacy findings did not establish sufficient weight-loss benefit to justify continuing its obesity development program.

This is an important distinction from compounds whose effectiveness has been established through successful, adequately controlled clinical trials.

What remains uncertain?

Important unanswered questions concern long-term safety, the effectiveness of different formulations, and whether any particular subgroup might experience a clinically meaningful effect. These possibilities should not be presented as established benefits without appropriate supporting research.

Why regulatory eligibility and effectiveness are separate

Even if a substance becomes eligible for a particular form of compounding, that does not demonstrate that it is effective for weight loss. Conversely, evidence of biological activity does not automatically make a substance eligible for compounding.

Scientific effectiveness, pharmaceutical quality, regulatory approval and compounding eligibility are separate considerations.

Responsible Scientific Communication for Peptide Brands

Accurate scientific and regulatory communication is particularly important in the peptide industry, where investigational compounds are sometimes marketed using claims that extend beyond the available evidence.

Peptide brands need educational content that distinguishes clinical findings from proposed mechanisms and commercial claims. This also applies to website development, search optimization and compliance monitoring, where inaccurate descriptions can create regulatory and reputational risks.

Peptide Ingenious provides peptide-specific SEO and Answer Engine Optimization (AEO), compliant website development, conversion rate optimization, ongoing compliance monitoring and email retention marketing for peptide businesses. Its official website provides further information about these digital services. Responsible digital communication should make scientific limitations and regulatory distinctions clear rather than presenting experimental peptides as proven treatments.

FAQs (Frequently Asked Questions)

What Is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone, with an additional tyrosine residue. It was developed as an experimental anti-obesity compound to investigate potential fat-metabolism effects. Although it has been studied in humans, it has not been approved as a weight-loss medication.

What Is AOD-9604 Used For?

AOD-9604 was originally investigated as a potential obesity treatment. Its research focused on possible effects on fat metabolism and weight reduction. It is not an FDA-approved medication, and its clinical development did not establish sufficient efficacy for an approved obesity treatment. Commercial descriptions of other uses should not be confused with established medical indications.

What Does AOD-9604 Do?

AOD-9604 was designed to investigate whether a fragment of human growth hormone could influence fat metabolism. Preclinical studies suggest potential effects on lipolysis and lipogenesis. However, controlled human research has not established that these proposed effects produce meaningful, sustained weight loss.

Does AOD-9604 Actually Work for Weight Loss?

AOD-9604 has undergone human obesity trials, including a pivotal 24-week study. The pivotal research did not establish statistically significant, clinically useful weight-loss efficacy. Although early studies generated interest in the compound, the overall clinical evidence does not support describing it as a proven weight-loss treatment.

What Are the Potential Benefits of AOD-9604?

Proposed benefits include changes in fat metabolism and potential effects on obesity and body composition. These hypotheses originated primarily from preclinical research. Human studies have not established clinically meaningful weight loss, reliable appetite suppression or improved muscle preservation. Claims about these benefits should therefore be interpreted as unproven.

What Are the Side Effects of AOD-9604?

Human studies have investigated AOD-9604's tolerability, but the available evidence does not establish a comprehensive long-term safety profile. The safety of different commercial formulations may also vary. Product purity, sterility and peptide-related impurities are additional concerns, particularly for unapproved preparations.

Is AOD-9604 FDA Approved?

No. AOD-9604 has not received FDA approval for weight loss or another therapeutic indication. Its historical clinical trials and its consideration in the FDA's compounding nomination process do not constitute drug approval. Commercial availability also does not establish that a product is FDA-approved.

Is AOD-9604 Returning to Legal Compounding?

As of October 1, 2026, the available FDA records do not establish a general return to legal compounding. AOD-9604's previous 503A nomination was withdrawn, which is not equivalent to its inclusion on the FDA's bulks list. Any future change would require assessment against the applicable federal and state requirements.

How Does AOD-9604 Compare With Semaglutide?

AOD-9604 is an experimental growth hormone fragment investigated for fat metabolism, while semaglutide is a GLP-1 receptor agonist with extensive clinical evidence. Semaglutide is an active ingredient in FDA-approved weight-management medications. AOD-9604 has not demonstrated comparable weight-loss efficacy in human trials.

How Does AOD-9604 Compare With Tirzepatide?

AOD-9604 and tirzepatide have different molecular structures and mechanisms. Tirzepatide activates GIP and GLP-1 receptors and has established weight-management efficacy in randomized trials. AOD-9604 was investigated for fat metabolism but did not establish sufficient efficacy in its pivotal obesity trial. They also have different FDA regulatory statuses.

Can AOD-9604 Be Combined With Tirzepatide?

There is insufficient controlled human evidence to establish the effectiveness or safety of combining AOD-9604 with tirzepatide. Evidence supporting tirzepatide alone cannot demonstrate that adding an experimental peptide improves outcomes. The safety and effectiveness of this combination remain unestablished.

Does AOD-9604 Suppress Appetite?

AOD-9604 is not an established appetite suppressant. Its original research focused on fat metabolism rather than the appetite-regulating pathways targeted by GLP-1 and GIP/GLP-1 medications. Reports of appetite changes in testimonials do not establish a consistent or clinically meaningful effect.

Is Oral AOD-9604 Effective?

Oral AOD-9604 formulations have been investigated in human clinical research. However, the clinical development program did not establish sufficient weight-loss efficacy. Evidence from experimental oral formulations cannot automatically be applied to commercially advertised capsules, tablets or other oral products.

Is AOD-9604 Available as a Nasal Spray?

AOD-9604 nasal sprays may be advertised commercially, but their availability does not establish clinical effectiveness or FDA approval. Adequate human clinical evidence demonstrating that marketed nasal spray formulations produce meaningful weight loss is lacking.

Are AOD-9604 Troches Proven to Work?

No. There is insufficient high-quality human evidence to establish that AOD-9604 troches produce meaningful weight loss. Troches have different formulation and absorption characteristics from other delivery systems, so evidence from another formulation cannot establish their effectiveness.

Does AOD-9604 Produce Visible Before-and-After Results?

There is no established, typical before-and-after outcome for AOD-9604. Photographs and testimonials cannot establish that the peptide caused a change in appearance. Reliable evidence requires controlled studies with objective measurements, appropriate comparison groups and adequate follow-up.

Is AOD-9604 Safe for Women?

Human research has not established a distinct, comprehensive female-specific safety profile for AOD-9604. Limited adverse-event reporting cannot prove that the peptide is safe for all women or that there are no sex-specific risks. More adequately powered research would be needed to answer these questions reliably.

Is AOD-9604 Effective for Bodybuilding?

AOD-9604 has not been established as a muscle-building or performance-enhancing treatment. Its proposed effects on fat metabolism do not demonstrate muscle growth, improved strength or athletic benefits. Human evidence for clinically meaningful improvements in body composition remains insufficient.

What is AOD-9604 and does it work for weight loss?

AOD-9604 is a synthetic fragment of human growth hormone investigated for its potential effects on fat metabolism. Although preclinical studies suggest possible lipolytic activity, human clinical trials have not established meaningful, sustained weight loss. It is not FDA-approved for obesity, and its current compounding status does not establish that it will soon become legally available.

Medical Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis or treatment recommendations. AOD-9604 is not an FDA-approved weight-loss medication, and its effectiveness and long-term safety have not been established. Information about investigational compounds should not be interpreted as an endorsement of their use. Readers should consult qualified healthcare professionals regarding medical conditions, weight management and medication-related questions.